High-Density Lipoproteins Decrease Proinflammatory Activity and Modulate the Innate Immune Response

Taborda, Natalia A.; Blanquiceth, Yurany; Urcuqui-Inchima, Silvio; Latz, Eicke; Hernández, Juan Carlos

doi:10.1089/jir.2019.0029

Cited by 27 publications

(22 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A statistically significant increase during the ICU stay was observed in LDL-C and HDL-C over time. No correlation was found between concentrations of LDL-C, HDL-C and mortality on day 28, which was close to [13] results.…”

supporting

confidence: 86%

COVID- 19 and abnormalities of some biochemical tests: review

Abdulbari

Al-Saadi

2021

QAJ

View full text Add to dashboard Cite

Coronaviruses are a group of viruses proven to affect both respiratory and gastrointestinal diseases in varied animal and human organisms. More than 100 million people worldwide are currently believed to have been infected and more than two million people have died and induced clinical syndrome of coronavirus disease in 2019.It's (COVID-19). The purpose of this analysis was to determine whether multiple biochemical test derangements are a common feature in patients with reported COVID-19 infection, to determine the relationship between the deranged liver test and lipoprotein with COVID-19 outcome or severity, and to determine whether liver failure or dyslipidemia is a common feature of COVID-19. This review was conducted using the Web of Science, PubMed and Scopus databases. English case-series and cross-sectional papers were considered, describing the currently offered findings on the relationship between certain biomedical tests and COVID-19 infections. To summarize, COVID-19 may have a severe tendency in older patients biochemical indexes (decrease albumin, decrease LDL-c, HDL-c, and TC, increased CRP, increased AST, increased LDH and CK) could be used as indicators to predict the severity of the disease.

show abstract

supporting

confidence: 86%

COVID- 19 and abnormalities of some biochemical tests: review

Abdulbari

Al-Saadi

2021

QAJ

View full text Add to dashboard Cite

show abstract

“…The studies in vitro showed that cholesterol on lipid rafts was proved to be required for the early stage of SARS-CoV replication and during the binding stage of SARS-CoV entering host cells [17] , [18] . Furthermore, HDL generally is an anti-inflammatory lipoprotein [19] , [20] , [21] . However, inflammation was reported to leads to structural alterations of HDL particles and caused the accumulation of the acute phase protein serum amyloid A (SAA) within the protein moiety of HDL [22] .…”

Section: Discussionmentioning

confidence: 99%

Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection

Dong

et al. 2020

Clinica Chimica Acta

149

151

View full text Add to dashboard Cite

show abstract

“…These chronic inflammatory states increase the risk of cardiovascular disease. HDL also is proved to be an anti-inflammatory lipoprotein [ 46 ]. It has been reported that inflammation leads to the structural changes of HDL granules and the accumulation of serum amyloid A (SAA).…”

Section: Discussionmentioning

confidence: 99%

Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis

Pan

Yin

et al. 2021

Virol J

View full text Add to dashboard Cite

Background The numbers of confirmed cases of coronavirus disease 2019 (COVID-19) and COVID-19 related deaths are still increasing, so it is very important to determine the risk factors of COVID-19. Dyslipidemia is a common complication in patients with COVID-19, but the association of dyslipidemia with the severity and mortality of COVID-19 is still unclear. The aim of this study is to analyze the potential association of dyslipidemia with the severity and mortality of COVID-19. Methods We searched the PubMed, Embase, MEDLINE, and Cochrane Library databases for all relevant studies up to August 24, 2020. All the articles published were retrieved without language restriction. All analysis was performed using Stata 13.1 software and Mantel–Haenszel formula with fixed effects models was used to compare the differences between studies. The Newcastle Ottawa scale was used to assess the quality of the included studies. Results Twenty-eight studies involving 12,995 COVID-19 patients were included in the meta-analysis, which was consisted of 26 cohort studies and 2 case–control studies. Dyslipidemia was associated with the severity of COVID-19 (odds ratio [OR] = 1.27, 95% confidence interval [CI] 1.11–1.44, P = 0.038, I2 = 39.8%). Further, patients with dyslipidemia had a 2.13-fold increased risk of death compared to patients without dyslipidemia (95% CI 1.84–2.47, P = 0.001, I2 = 66.4%). Conclusions The results proved that dyslipidemia is associated with increased severity and mortality of COVID-19. Therefore, we should monitor blood lipids and administer active treatments in COVID-19 patients with dyslipidemia to reduce the severity and mortality.

show abstract

High-Density Lipoproteins Decrease Proinflammatory Activity and Modulate the Innate Immune Response

Cited by 27 publications

References 76 publications

COVID- 19 and abnormalities of some biochemical tests: review

COVID- 19 and abnormalities of some biochemical tests: review

Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection

Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis

Contact Info

Product

Resources

About